This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Ophthalmic disease				
Age-related macular degeneration (AMD)	MicroRNA-23 (miR-23); miR-27	<p>Mouse studies suggest inhibiting miR-23 or miR-27 could help treat AMD and other vascular diseases. In mice, subretinal injection of anti-miRNAs against miR-23 or miR-27 decreased angiogenic sprouting distance and vessel coverage in neonatal eyes compared with injection of scrambled control miRNA. In a mouse model of AMD, the anti-miRNAs repressed choroidal neovascularization by more than 50% compared with scrambled control miRNA. Next steps could include testing the anti-miRNAs in other preclinical models of vascular disease.</p> <p>SciBX 4(20); doi:10.1038/scibx.2011.582 Published online May 19, 2011</p>	Patent and licensing status unavailable	<p>Zhou, Q. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online May 2, 2011; doi:10.1073/pnas.1105254108 Contact: Shusheng Wang, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas e-mail: Shusheng.Wang@utsouthwestern.edu Contact: Eric N. Olson, same affiliation as above e-mail: Eric.Olson@utsouthwestern.edu</p>